Health Department OKs LITFULO for severe alopecia

In Singapore, the local incidence of alopecia areata is 3.8%.

The Health Sciences Authority has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.

Pfizer Singapore, the drug’s developer, said that patients can now access the treatment at specialist clinics and hospitals islandwide.

In Singapore, the local incidence of alopecia areata is 3.8% with patients with severe alopecia less likely to experience full remission and regrowth, as compared to patients with milder forms of alopecia areata.

The drug is a kinase inhibitor that inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) family of kinases.

The approval was based on the results of the ALLEGRO Phase 2b/3 trial, which enrolled 718 patients with at least 50% scalp hair loss as measured by the Severity of Alopecia Tool
(SALT), evaluating the efficacy and safety of LITFULO.

Results showed that 23% of patients treated with LITFULO 50 mg had 80% or more scalp hair coverage (SALT≤20) after 24 weeks compared to 2% with placebo. LITFULO was effective and well-tolerated in patients aged 12 years and older.

However, the most common adverse events reported in patients include headache, nasopharyngitis, upper respiratory tract infection, nausea, and acne.

Follow the link for more news on

Pfizer

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia